ADIL.US Adial Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
5.05 USD
Close of Nov 12, 2026
0.0042 7.20
Market cap
USD 13.3M
P/E
-
P/B
3.53x
ROE
-69,245.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ADIL.US undervalued?

Graham number

The Graham number of Adial Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Adial Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Adial Pharmaceuticals Inc yet.

Adial Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Adial Pharmaceuticals Inc

As of June 11, 2026, Adial Pharmaceuticals, Inc. was acquired by Azora Therapeutics, Inc. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for no…

Full company profile